Every Form 4 that GH Research PLC (GHRS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GHRS filings page.
GH Research PLC (GHRS) reported that director Florian Schonharting2,303 share options$0.025 per Ordinary Share, are immediately fully vested, but are not exercisable until September 8, 2028, and expire on September 8, 2033. Following this award, he holds 2,303 share options directly.
GH Research PLC director Duncan Moore received a compensatory grant of 2,202 share options on 2026-08-11. The options carry an exercise price of 0.0250 per ordinary share and expire on 2033-08-11. They are immediately fully vested but are not exercisable until August 11, 2028.
GH Research PLC director Dermot John Hanley received a grant of share options covering 2,202 underlying ordinary shares on August 11, 2026. The options have an exercise price of $0.025 per share, are immediately fully vested, but are not exercisable until August 11, 2028, and expire on August 11, 2033. Following this grant, Hanley holds 2,202 share options directly.
GH Research PLC director Michael Forer reported two grants of share options over Ordinary Shares. One grant covers 2,202 options at an exercise price of $0.0250 per share, which are immediately fully vested but not exercisable until August 11, 2028 and expire on August 11, 2033. A second grant covers 100,000 options at the same exercise price, expiring August 11, 2033, with 25% vesting and becoming exercisable on August 11, 2027 and the remaining 75% vesting in equal monthly installments over three years thereafter.